IRF1-IN-2-生命科學(xué)試劑-MCE-4888

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEIRF1-IN-2Cat.No.:HY-171007CASNo.:708245-32-3分?式:C??H??N?O?S分?量:360.43作?靶點(diǎn):Caspase;PARP;Pyroptosis;InterleukinRelated;GlutathionePeroxidase;IFNAR作?通路:Apoptosis;CellCycle/DNADamage;Epigenetics;Immunology/Inflammation;MetabolicEnzyme/Protease儲(chǔ)存?式:4°C,sealedstorage,awayfrommoisture*Insolvent:-80°C,6months;-20°C,1month(sealed

storage,awayfrommoisture)溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:125mg/mL(346.81mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM2.7745mL13.8723mL27.7446mL5mM0.5549mL2.7745mL5.5489mL10mM0.2774mL1.3872mL2.7745mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month(sealedstorage,awayfrommoisture)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。BIOLOGICALACTIVITY?物活性IRF1-IN-2(CompoundI-19)?種IRF1抑制劑。IRF1-IN-2可減少IRF1對(duì)CASP1啟動(dòng)?的招募。IRF1-IN-2抑制細(xì)胞死亡信號(hào)通路(即抑制Caspase1、GSDMD、IL-1和PARP1的裂解；抑制TKB1的磷酸化，上調(diào)GPX4并下調(diào)FACL4)。IRF1-IN-2對(duì)電離輻射引起的?膚炎癥性損傷有保護(hù)作?[1]。IC50&TargetPARP-1IL-1Caspase-11/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE體外研究IRF1-IN-2pretreatment(20μM,12?h)decreasestherecruitmentofIRF1tothepromoterofCASP1inirradiatedHaCaTcells(20?Gy)[1].IRF1-IN-2(20μM,24h)attenuatestheNSP-10plasmidtransfection-inducedIRF1activationinHELFandWS1cells[1].IRF1-IN-2protectsA375cellsagainstradiation(20Gy)[1].IRF1-IN-2inhibitscelldeathsignalingpathways,includinginhibitionofcleavageforCaspase1,GSDMD,IL-1andPARP1,phosphorylationofTKB1,up-regulationofGPX4anddown-regulationofFACL4[1].IRF1-IN-2maintainsmitochondrialactivityandROSproductioninskincellsintheearlystageafterirradiation[1].體內(nèi)研究IRF1-IN-2pretreatment(100?μg/d,s.c.,oneeveryotherdaybeforeirradiation)hasapotentialprotectiveeffectin35Gyradiation-inducedinflammatoryskininjurymice[1].AnimalModel:Radiogenicskininjurymice(intraperitonealinjectionofpentobarbitalsodium(1%,30mg/kg),35Gyatthedoserateof1000cGy/minbya6-MeVelectronbeam)[1]Dosage:100μg/dAdministration:Subcutaneousinjection(s.c.),oneeveryotherdaybeforeirradiation,pretreatmentResult:Showedasignificantreductioninacuteskininflammatorymanifestations,suchaserythemaandexudation.Showedprotectiveeffectsonthefunctionandstructuralintegrityofradiation-inducedlesionstotheclaws.REFERENCES[1].Geng,etal.Chaperone-andPTM-mediatedactivationofIRF1tamesradiation-inducedcelldeathandtheinflammatoryresponse.CellMolImmunol.2024Aug;21(8):856-872.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplica